NCT00943670View on ClinicalTrials.gov

Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

December 31, 2010

Study Completion Date

August 31, 2011

Conditions
Metastatic Breast Cancer
Interventions
BIOLOGICAL

pertuzumab

Intravenous repeating dose

BIOLOGICAL

Trastuzumab emtansine [Kadcyla]

Intravenous repeating dose

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY

NCT00943670 - Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression | Biotech Hunter | Biotech Hunter